Reuters logo
BRIEF-Rosetta Genomics up in premarket after tumor study data
January 9, 2013 / 2:01 PM / 5 years ago

BRIEF-Rosetta Genomics up in premarket after tumor study data

NEW YORK, Jan 9 (Reuters) - Rosetta Genomics Ltd : * Up 19 percent to $5.48 in premarket after tumor study data

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below